Katherine Francisco
About Katherine Francisco
Katherine Francisco is a Research Associate II in In Vivo Oncology at Alkermes, with extensive experience in in vivo oncology research and a robust background in biotechnology.
Current Position at Alkermes
Katherine Francisco is currently working at Alkermes as a Research Associate II in the In Vivo Oncology department. In this role, she applies her extensive experience in in vivo oncology research, focusing on data collection, analysis, and presentation within the context of oncology studies.
Previous Roles at ImmunoGen, Inc.
Katherine Francisco has accumulated significant experience at ImmunoGen, Inc., where she served in multiple capacities. Her roles included Research Associate I in In-Vivo Pharmacology for six months from 2018 to 2019, Senior Research Technician in Pharmacology for one year from 2017 to 2018, Research Associate Intern from 2016 to 2017, and Animal Technician II from 2014 to 2017. These positions were based in Waltham, MA, and provided her with a solid foundation in pharmacology and animal care.
Early Career in Biotechnology and Animal Care
Before her tenure at ImmunoGen, Inc., Francisco worked as an Animal Caretaker at Tufts University from 2013 to 2014 in Medford, MA, and as a Technician I at Charles River Laboratories in 2012 for six months. These early roles helped her develop her expertise in animal care and laboratory practices, setting the stage for her future work in pharmacology and oncology research.
Educational Background in Biomedical Sciences
Katherine Francisco holds a Bachelor's Degree in Biomedical Laboratory and Clinical Sciences from Boston University, where she studied from 2014 to 2017. She also earned an Associate's degree and a Biotechnology Certificate from Middlesex Community College. This robust educational background underpins her career in biotechnology and in vivo oncology research.
Skills and Expertise in In Vivo Oncology
Katherine Francisco possesses strong skills in data collection, analysis, and presentation, particularly within the context of in vivo studies. She has significant expertise in in vivo oncology research, having worked in this field since 2019. Her background in the biotechnology industry includes a robust focus on in vivo pharmacology and oncology.